References
Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff R, Salusky IB (2003) Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 18:1260–1264
Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252
Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527–531
Salusky IB, Kuizon BD, Belin T, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907–914
Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483
Hergesell O, Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863–867
Joy MS, Finn WF (2003) Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96–107
Eknoyan G, Levin A, Levin NW (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease—foreword. Am J Kidney Dis 42:S7–S201
Collins AJ, St.Peter WL, Dalleska FW, Ebben JP, Ma JZ (2000) Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 54:334–341
Author information
Authors and Affiliations
Corresponding author
Additional information
This reply refers to the Letter to the Editors at http://dx.doi.org/10.1007/s00467–004–1535–8
Rights and permissions
About this article
Cite this article
Salusky, I.B., Elashoff, R. Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna. Pediatr Nephrol 19, 947–948 (2004). https://doi.org/10.1007/s00467-004-1531-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-004-1531-z